Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Amylyx Pharmaceuticals, Inc. (AMLX) is a Biotechnology company based in US with a market capitalization of $1.2B. Free cash flow was negative at -$123.5M. This page tracks AMLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 123 employees · IPO Jan 7, 2022
Valuation
Valuation & price
$13.29as of May 17, 2026· -29.0% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.84
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.2B
Market cap
—
Revenue growth (YoY)
51.8%
Gross margin
-$123.5M
Free cash flow (USD)
-$311M
Net debt
Net cash position
38.8%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2022 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Amylyx Pharmaceuticals, Inc.'s market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $1.2B.
What is AMLX's P/E ratio?
A meaningful P/E ratio is not available for AMLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is AMLX's price-to-book (P/B) ratio?
AMLX trades at 3.84 times book value per share.
Are insiders buying AMLX stock?
SEC Form 4 filings show no open-market insider buys at Amylyx Pharmaceuticals, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.